Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Cp (NQ: ABUS )

1.895 -0.035 (-1.81%)
Streaming Delayed Price Updated: 3:39 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arbutus Biopharma Cp

< Previous 1 2 3 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, trader! We're ready for another busy week of trading as we start it with the biggest pre-market stock movers for Monday! 
Via InvestorPlace
The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura... 
Via Benzinga
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current 
Via Talk Markets
25 Stocks Moving in Monday's Pre-Market Session
Gainers Society Pass Incorporated (NASDAQ: SOPA) rose 68% to $5.59 in pre-market trading after the company reported addition to the Russell 2000 Index. Verso Corporation (NYSE:... 
Via Benzinga
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board
BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai. 
Via Talk Markets
How Will Moderna Stock Weather Omicron? — And Other Questions Clouding 2022
Analysts call for a sales and earnings decline in 2022. Can Moderna stave it off? 
Via Investor's Business Daily
Why Arbutus Biopharma Shares Are Rising
Arbutus Biopharma Corp (NASDAQ: ABUS) shares are trading higher after the company announced it received a $40M upfront payment from Qilu to commercialize AB-729 in Asia... 
Via Benzinga
Arbutus Biopharma Shares Jump After Achieving First Milestone Under COVID-19 Pact
Arbutus Biopharma Corporation (NASDAQ: ABUS) has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for treating... 
Via Benzinga
Exposures COVID-19
20 Stocks Moving in Friday's Pre-Market Session
Gainers BIOLASE, Inc. (NASDAQ: BIOL) rose 27.2% to $0.52 in pre-market trading. Biolase reporte in Form4 filing that President bought 70,000 shares at an average price of $0.45... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! We're gearing up for another busy day of trading with the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
27 Stocks Moving in Thursday's Pre-Market Session
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 25.8% to $4.09 in pre-market trading after surging around 12% on Wednesday. Digital World Acquisition Corp. (NASDAQ: DWAC)... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Moderna Stock Plunged Today
A patent dispute could pressure the vaccine maker's profits. 
Via The Motley Fool
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Mid-Afternoon Market Update: Dow Rises Over 100 Points; CTI BioPharma Shares Plummet
Toward the end of trading Wednesday, the Dow traded up 0.39% to 34,617.2 while the NASDAQ climbed 0.17% to 15,564.73. The S&P also rose, gaining 0.68% to 4,597.96. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Arbutus' Hepatitis B Candidate Shows Encouraging Antiviral Activity
Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced preliminary data from its Phase 1a/1b trial of AB-836, an oral hepatitis B virus (HBV) capsid inhibitor... 
Via Benzinga
ABUS Stock Alert: The Moderna News That Has Arbutus Biopharma Shares Rocketing Today
Arbutus Biopharma (ABUS) stock is taking off on Wednesday thanks to a court ruling in its favor in a case against Moderna (MRNA). 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Why Arbutus Shares Are Soaring Today
Arbutus Biopharma Corp (NASDAQ: ABUS) is soaring Wednesday after The Patent Trial and Appeals Board turned down Moderna Inc's (NASDAQ: MRNA) appeal to... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Mid-Day Market Update: Build-A-Bear Jumps After Q3 Results; BeyondSpring Shares Slide
Midway through trading Wednesday, the Dow traded up 1.06% to 34,847.76 while the NASDAQ climbed 1.17% to 15,719.00. The S&P also rose, gaining 1.48% to 4,634.64. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial and Appeals Board has turned down Moderna's... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Arbutus Biopharma Is Rocketing Higher Today
A recent court of appeals decision is bad news for Moderna and great news for Arbutus Biopharma. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Why Moderna Shares Are Sliding Today
Moderna Inc (NASDAQ: MRNA) is trading lower Wednesday after The Patent Trial and Appeals Board turned down the company's appeal to invalidate two of Arbutus Biopharma... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Arbutus Shares Are Soaring As Moderna Loses Appeal Of Board Ruling On COVID-19 Vaccine Delivery Technology Patent
Shares of small-cap biotech Arbutus Biopharma Corporation (NASDAQ: ABUS) are advancing strongly on above-average volume on Wednesday. What Happened: The Patent Trial and Appeals... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Mid-Morning Market Update: Markets Open Higher; G-III Apparel Earnings Beat Views
Following the market opening Wednesday, the Dow traded up 0.99% to 34,824.47 while the NASDAQ climbed 1.40% to 15,755.57. The S&P also rose, gaining 1.39% to 4,630.57. The U.S... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, trader! We're starting off the week strong with a dive into the biggest pre-market stock movers for Monday. 
Via InvestorPlace
26 Stocks Moving in Monday's Pre-Market Session
Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. Syncona said Blackstone Life Science will invest $250 million in Autolus. Mainz Biomed... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Arbutus Biopharma (ABUS) Q3 2021 Earnings Call Transcript
ABUS earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
21 Stocks Moving in Monday's Pre-Market Session
Gainers Valneva SE (NASDAQ: VALN) rose 34.4% to $37.69 in pre-market trading after the company disclosed positive Phase 3 results for inactivated, adjuvanted COVID-19 vaccine... 
Via Benzinga
Exposures COVID-19
60 Biggest Movers From Friday
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in... 
Via Benzinga
41 Stocks Moving In Friday's Mid-Day Session
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares climbed 64.4% to $14.29 after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in geographic... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.